top of page
Writer's pictureIndian Pharma

Enhertu: Indication and Dosage of the medicine



The medicine Enhertu has fam-trastuzumab deruxtecan-nxki as the active ingredient. The drug, Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate recommended for treating adult patients with breast cancer, non-small cell lung cancer and gastric or gastroesophageal junction adenocarcinoma. This drug comes in 100 mg lyophilized powder in a single-dose vial for intravenous infusion.

Indications

One can use the medicine Enhertu 100 mg for treating patients with:

  • HER2-positive breast cancer

Healthcare professionals recommend this medicine to adult patients who have unresectable/metastatic HER2-positive breast cancer who have received a prior anti-HER2-based routine either:

in the metastatic setting, or

in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of treatment completion.

  • HER2-low breast cancer

Healthcare providers indicate Enhertu in adult patients with unresectable/metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast carcinoma who have receive chemotherapy earlier in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

  • Non-small cell lung cancer (NSCLC)

Adult patients are recommended to take Enhertu with unresectable/metastatic non-small cell lung cancer whose tumors have activating HER2 (ERBB2) mutations, detected by an FDA-approved test, and who have received systemic therapy earlier.

  • Gastric or gastroesophageal junction adenocarcinoma

Healthcare professionals recommend administering Enheru to adult patients who have locally advanced or metastatic HER2-positive gastric/gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen earlier.


Dosage

One should not substitute Enhertu for or with trastuzumab or ado-trastuzumab emtansine.

One can slow or interrupt the infusion rate if the patient develops infusion-related symptoms.

One should permanently discontinue Enhertu in case of severe infusion reactions.


Dosage for Metastatic Breast Cancer

Enhertu recommended dosage is 5.4 mg/kg administered intravenously once every 3 weeks (21-day) until disease progression or unacceptable toxicity.


Dosage for Unresectable or Metastatic HER2-Mutant (NSCLC)

Enhertu 100 mg injection recommended dosage is 5.4 mg/kg administered intravenously once every 3 weeks (21-day) until disease progression or unacceptable toxicity.

Locally Advanced or Metastatic Gastric Cancer Dosage

Enhertu recommended dosage is 6.4 mg/kg administered intravenously once every 3 weeks (21 days) until disease progression or unacceptable toxicity.


Price: Enhertu

If you want to buy enhertu online in India, contact us at +91 93100 90915 or at info@theindianpharma.com.

Recent Posts

See All

Tukysa: Indications and Uses

The medicine Tuksya containing Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and...

Comments


bottom of page